Prometheus Biosciences (RXDX) Stock Forecast, Price Target & Predictions
RXDX Stock Forecast
Prometheus Biosciences stock forecast is as follows: an average price target of $138.57 (represents a -30.69% downside from RXDX’s last price of $199.92) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
RXDX Price Target
The average price target for Prometheus Biosciences (RXDX) is $138.57 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $200.00 to $67.00. This represents a potential -30.69% downside from RXDX's last price of $199.92.
RXDX Analyst Ratings
According to 7 Wall Street analysts, Prometheus Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RXDX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Prometheus Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 16, 2023 | Annabel Samimy | Stifel Nicolaus | $200.00 | $114.01 | 75.42% | 0.04% |
| Jan 31, 2023 | - | Goldman Sachs | $144.00 | $113.66 | 26.69% | -27.97% |
| Dec 08, 2022 | Jeff Jones | Oppenheimer | $125.00 | $117.21 | 6.65% | -37.47% |
| Dec 08, 2022 | Gregory Renza | RBC Capital | $111.00 | $117.21 | -5.30% | -44.48% |
| Dec 08, 2022 | Julian Harrison | BTIG | $181.00 | $117.21 | 54.42% | -9.46% |
| Dec 08, 2022 | Tiago Fauth | Credit Suisse | $142.00 | $117.21 | 21.15% | -28.97% |
| Dec 08, 2022 | Julian Harrison | BTIG | $104.84 | $95.80 | 9.44% | -47.56% |
| Aug 28, 2022 | Yasmeen Rahimi | Piper Sandler | $67.00 | $49.40 | 35.63% | -66.49% |
| Jun 10, 2022 | Yasmeen Rahimi | Piper Sandler | $53.00 | $26.35 | 101.14% | -73.49% |
The latest Prometheus Biosciences stock forecast, released on Apr 16, 2023 by Annabel Samimy from Stifel Nicolaus, set a price target of $200.00, which represents a 75.42% increase from the stock price at the time of the forecast ($114.01), and a 0.04% increase from RXDX last price ($199.92).
Prometheus Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $199.92 | $199.92 | $199.92 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Prometheus Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prometheus Biosciences's last price of $199.92. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 31, 2023 | Goldman Sachs | Buy | Buy | Hold |
| Dec 08, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Dec 08, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Dec 08, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Dec 08, 2022 | BTIG | Buy | Buy | Hold |
| Oct 04, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 04, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Aug 29, 2022 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 28, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 10, 2022 | Piper Sandler | - | Overweight | Initialise |
Prometheus Biosciences's last stock rating was published by Goldman Sachs on Jan 31, 2023. The company gave RXDX a "Buy" rating, the same as its previous rate.
Prometheus Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ETNB | 89bio | $8.48 | $22.00 | 159.43% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| VKTX | Viking Therapeutics | $66.73 | $100.50 | 50.61% | Buy |
| IMVT | Immunovant | $29.67 | $42.83 | 44.35% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| ROIV | Roivant Sciences | $11.94 | $15.36 | 28.64% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KRYS | Krystal Biotech | $201.58 | $191.00 | -5.25% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |
RXDX Forecast FAQ
Is Prometheus Biosciences a good buy?
Yes, according to 7 Wall Street analysts, Prometheus Biosciences (RXDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of RXDX's total ratings.
What is RXDX's price target?
Prometheus Biosciences (RXDX) average price target is $138.57 with a range of $67 to $200, implying a -30.69% from its last price of $199.92. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Prometheus Biosciences stock go up soon?
According to Wall Street analysts' prediction for RXDX stock, the company can go down by -30.69% (from the last price of $199.92 to the average price target of $138.57), up by 0.04% based on the highest stock price target, and down by -66.49% based on the lowest stock price target.
Can Prometheus Biosciences stock reach $300?
RXDX's average twelve months analyst stock price target of $138.57 does not support the claim that Prometheus Biosciences can reach $300 in the near future.